← Eichor
Study identifier: NCT04863950 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Condition: Glioblastoma  ·  Sponsor: The University of Texas Health Science Center at San Antonio

PhasePhase 2
Planned participants25
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.

This description comes directly from the study's public registry record.

Talk to the study team

Epp Goodwin  ·  210 450 5798  ·  goodwine@uthscsa.edu

Maggie Tomasini  ·  210 450 5962  ·  tomasinim@uthscsa.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Mays Cancer Center, UT Health San AntonioSan Antonio, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04863950